Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination ...

Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.

The company plans to focus its resources on conducting clinical trials for CD388 influenza prevention therapy.

Sobi and Enable Injections have entered an agreement for the development and distribution of Aspaveli in combination with ...

The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...

R&D frameworks are in place for the next pandemic-causing pathogen, but ways to derisk development are unclear.

Sanofi has signed a licensing agreement with RadioMedix and Orano Med to advance a radioligand therapy, AlphaMedix.

Lilly has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked for ...

Moderna will slash five clinical programmes but says it remains on track for ten product approvals in the next three years.

The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficacy in reducing blood glucose and weight.

The vaccine manufacturer said it could also supply 13 million doses by YE 2025 to meet requests by Africa CDC and UNICEF.

Agios Pharmaceuticals has announced that the US FDA has granted orphan drug designation to tebapivat to treat myelodysplastic syndromes.